RENE TORRES: Open Payments
NPI 1811155534 · MCALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$862 in 45 payments from 12 companies in 2025. Trend: 2023 $1,432 · 2024 $1,260 · 2025 $862
Food & beverage: $862
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 19 | $219 |
| AstraZeneca Pharmaceuticals LP | 4 | $139 |
| Dexcom, Inc. | 1 | $116 |
| Amgen Inc. | 6 | $101 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $70 |
| Lilly USA, LLC | 3 | $54 |
| Corcept Therapeutics | 2 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
Products named: FARXIGA, Dexcom G6 Transmitter, Wegovy, OTEZLA, JARDIANCE, MOUNJARO, Ozempic, Korlym.
Industry payments across TX — which companies pay providers there.
